Autosomal dominant polycystic kidney disease: updated perspectives

References

• Igarashi P, Somlo S, Editor F. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2002;13(9):2384–2398. doi:10.1097/01.ASN.0000028643.17901.4212191984
   PubMed Web of Science ®Google Scholar
• Helal I. Autosomal dominant polycystic kidney disease: new insights into treatment. Saudi J Kidney Dis Transpl. 2013;24(2):230–234. doi:10.4103/1319-2442.10956123538343
   PubMedGoogle Scholar
• Spithoven EM, Kramer A, Meijer E, et al. Analysis of data from the ERA-EDTA registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 2014;86(6):1244–1252. doi:10.1038/ki.2014.12024827775
   PubMed Web of Science ®Google Scholar
• Collins AJ, Foley RN, Chavers B, et al. US renal data system 2011 annual data report. Am J Kidney Dis. 2012;59(1):A7. doi:10.1053/j.ajkd.2011.11.01522177944
   PubMed Web of Science ®Google Scholar
• Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792–810. doi:10.1053/j.ajkd.2015.07.03726530876
   PubMed Web of Science ®Google Scholar
• Grantham JJ. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–1485. doi:10.1056/NEJMcp080445818832246
   PubMed Web of Science ®Google Scholar
• Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2005;1(1):148–157. doi:10.2215/CJN.0033070517699202
   PubMed Web of Science ®Google Scholar
• Chapman AB, Devuyst O, Eckardt K-U, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27. doi:10.1038/ki.2015.5925786098
   PubMed Web of Science ®Google Scholar
• Aguiari G, Catizone L, Del Senno L. Multidrug therapy for polycystic kidney disease: a review and perspective. Am J Nephrol. 2013;37(2):175–182. doi:10.1159/00034681223428809
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol. 2018;29(1):13–23. doi:10.1681/ASN.201705048329038287
   PubMed Web of Science ®Google Scholar
• Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort1. Kidney Int. 2003;64(3):1035–1045. doi:10.1046/j.1523-1755.2003.00185.x12911554
   PubMed Web of Science ®Google Scholar
• Gabow P. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–1485. doi:10.1136/bmj.i67918832246
   PubMed Web of Science ®Google Scholar
• Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13(11):1765–1776. doi:10.2215/CJN.0396031830049849
   PubMed Web of Science ®Google Scholar
• Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205–212. doi:10.1681/ASN.200805050718945943
   PubMed Web of Science ®Google Scholar
• Pei Y, Hwang Y-H, Conklin J, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2015;26(3):746–753. doi:10.1681/ASN.201403029725074509
   PubMed Web of Science ®Google Scholar
• Nguyen A-NT, Wallace DP, Blanco G. Ouabain binds with high affinity to the Na,K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol. 2007;18(1):46–57. doi:10.1681/ASN.200601008617151336
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Chebib FT, Madsen CD, et al. The value of genetic testing in polycystic kidney diseases illustrated by a family with PKD2 and COL4A1 mutations. Am J Kidney Dis. 2018;72(2):302–308. doi:10.1053/j.ajkd.2017.11.01529395486
   PubMed Web of Science ®Google Scholar
• Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122–2130. doi:10.1056/NEJMoa05434116707749
   PubMed Web of Science ®Google Scholar
• Tangri N, Hougen I, Alam A, Perrone R, Mcfarlane P, Pei Y. Total kidney volume as a biomarker of disease progression in autosomal dominant polycystic kidney disease. Can J Kidney Health Dis. 2017;4:2054358117693355. doi:10.1177/205435811769335528321323
   PubMedGoogle Scholar
• Kühn EW, Walz G. The treatment of autosomal dominant polycystic kidney disease. Dtsch Arztebl Int. 2015;112(51–52):884. doi:10.3238/arztebl.2015.088426900155
   PubMed Web of Science ®Google Scholar
• Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479. doi:10.2215/cjn.0950091122344503
   PubMed Web of Science ®Google Scholar
• Bhutani H, Smith V, Rahbari-Oskoui F, et al. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146–151. doi:10.1038/ki.2015.7125830764
   PubMed Web of Science ®Google Scholar
• Meijer E, Visser FW, van Aerts RMM, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease. JAMA. 2018;320(19):2010. doi:10.1001/jama.2018.1587030422235
   PubMed Web of Science ®Google Scholar
• Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017;13(12):750–768. doi:10.1038/nrneph.2017.12728989174
   PubMed Web of Science ®Google Scholar
• Torres VE. Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2019;34(1):30–34. doi:10.1093/ndt/gfy29730312438
   PubMed Web of Science ®Google Scholar
• Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl- secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. AJP Ren Physiol. 2011;301(5):F1005–F1013. doi:10.1152/ajprenal.00243.2011
   Google Scholar
• Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE. Vasopressin and disruption of calcium signalling in polycystic kidney disease. Nat Rev Nephrol. 2015;11(8):451–464. doi:10.1038/nrneph.2015.3925870007
   PubMed Web of Science ®Google Scholar
• Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol. 2015;308(3):F261–F266. doi:10.1152/ajprenal.00345.201425503729
   PubMed Web of Science ®Google Scholar
• Zittema D, Boertien WE, van Beek AP, et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol. 2012;7(6):906–913. doi:10.2215/CJN.1131111122516290
   PubMed Web of Science ®Google Scholar
• Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1140–1150. doi:10.2215/CJN.0079020919443627
   PubMed Web of Science ®Google Scholar
• Clark WF, Devuyst O, Roussel R. The vasopressin system: new insights for patients with kidney diseases. J Intern Med. 2017;282(4):310–321. doi:10.1111/joim.1265428905441
   PubMed Web of Science ®Google Scholar
• Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years’ experience. Clin J Am Soc Nephrol. 2011;6(10):2499–2507. doi:10.2215/CJN.0353041121903984
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Torres VE, Hogan MC, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2011;80(3):295–301. doi:10.1038/ki.2011.11921544064
   PubMed Web of Science ®Google Scholar
• Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic kidney disease and its outcomes) 3–4 study. Am J Kidney Dis. 2011;57(5):692–699. doi:10.1053/j.ajkd.2010.11.02921333426
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa120551123121377
   PubMed Web of Science ®Google Scholar
• Casteleijn NF, Blais JD, Chapman AB, et al. Tolvaptan and kidney pain in patients with autosomal dominant polycystic kidney disease: secondary analysis from a randomized controlled trial. Am J Kidney Dis. 2017;69(2):210–219. doi:10.1053/j.ajkd.2016.08.02827856088
   PubMed Web of Science ®Google Scholar
• Devuyst O, Chapman AB, Gansevoort RT, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28(5):1592–1602. doi:10.1681/ASN.201604044827920153
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2018;33(3):477–489. doi:10.1093/ndt/gfx04328379536
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017:NEJMoa1710030. doi:10.1056/NEJMoa1710030
   Web of Science ®Google Scholar
• Gy ECOLO. News & views: tolvaptan slows disease progression in late-stage ADPKD. Nat Publ Gr. 2015;1–2. doi:10.1038/nature16329
   Google Scholar
• Rizvi NA, Peters S. Tolvaptan and autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1986–1988. doi:10.1056/NEJMe171143029141165
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO) Lipid Work Group. Clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013;3(3):259–305. doi:10.7326/M13-2453
   Web of Science ®Google Scholar
• Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513–519. doi:10.1016/S0272-6386(12)80922-X8213789
   PubMed Web of Science ®Google Scholar
• A Practical Guide for Treatment of Rapidly Progressive (1).pdf.
   Google Scholar
• Perrone RD, Mouksassi M-S, Romero K, et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep. 2017;2(3):442–450. doi:10.1016/j.ekir.2017.01.00329142971
   PubMed Web of Science ®Google Scholar
• Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–172. doi:10.1681/ASN.201310113824904092
   PubMed Web of Science ®Google Scholar
• O’Neill WC, Robbin ML, Bae KT, et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005;46(6):1058–1064. doi:10.1053/j.ajkd.2005.08.02616310571
   PubMed Web of Science ®Google Scholar
• Girardat-Rotar L, Braun J, Puhan MA, Abraham AG, Serra AL. Temporal and geographical external validation study and extension of the mayo clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients. BMC Nephrol. 2017;18(1):241. doi:10.1186/s12882-017-0654-y28716055
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant. 2016;31(3):337–348. doi:10.1093/ndt/gfv45626908832
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Audrézet M-P, Rousseau A, et al. The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2016;27(3):942–951. doi:10.1681/ASN.201501001626150605
   PubMed Web of Science ®Google Scholar
• Cornec-Le Gall E, Audrezet M-P, Chen J-M, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006–1013. doi:10.1681/ASN.201207065023431072
   PubMed Web of Science ®Google Scholar
• Boertien WE, Meijer E, de Jong PE, et al. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis. 2015;65(6):833–841. doi:10.1053/j.ajkd.2014.11.01025600953
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Meijer E, Chapman AB, et al. Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 trial. Nephrol Dial Transplant. 2016;31(11):1887–1894. doi:10.1093/ndt/gfv42226681730
   PubMed Web of Science ®Google Scholar
• Watkins PB, Lewis JH, Kaplowitz N, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38(11):1103–1113. doi:10.1007/s40264-015-0327-326188764
   PubMed Web of Science ®Google Scholar
• Kramers BJ, van Gastel MDA, Meijer E, Gansevoort RT. Case report: a thiazide diuretic to treat polyuria induced by tolvaptan. BMC Nephrol. 2018;19(1):157. doi:10.1186/s12882-018-0957-729970015
   PubMed Web of Science ®Google Scholar
• Wang A, Hirose T, Ohsaki Y, et al. Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats. Clin Exp Nephrol. 2018. doi:10.1007/s10157-018-1669-9
   Web of Science ®Google Scholar
• Amro OW, Paulus JK, Noubary F, Perrone RD. Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. Am J Kidney Dis. 2016;68(6):882–891. doi:10.1053/j.ajkd.2016.07.02327663039
   PubMed Web of Science ®Google Scholar
• Müller R-U, Benzing T. Management of autosomal-dominant polycystic kidney disease-state-of-the-art. Clin Kidney J. 2018;11(Suppl 1):i2–i13. doi:10.1093/ckj/sfy10330581561
   PubMed Web of Science ®Google Scholar
• Rahbari-Oskoui F, Williams O, Chapman A. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29(12):2194–2201. doi:10.1093/ndt/gft51324463189
   PubMed Web of Science ®Google Scholar
• Schrier RW. Decade in review—polycystic kidney disease: slowing progression of autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2015;11(11):638–639. doi:10.1038/nrneph.2015.16426460355
   PubMed Web of Science ®Google Scholar
• Cerasola G, Vecchi ML, Mulè G, et al. Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives. Am J Nephrol. 1998;18(5):391–398. doi:10.1159/0000133829730562
   PubMed Web of Science ®Google Scholar
• Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010;17(2):153–163. doi:10.1053/j.ackd.2010.01.00120219618
   PubMed Web of Science ®Google Scholar
• Rysz J, Gluba-Brzózka A, Franczyk B, Banach M, Bartnicki P. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Pharmacother. 2016;17(15):2049–2056. doi:10.1080/14656566.2016.123239427650472
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abebe KZ, Perrone RD, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371(24):2255–2266. doi:10.1056/NEJMoa140268525399733
   PubMed Web of Science ®Google Scholar
• Ong ACM, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385(9981):1993–2002. doi:10.1016/S0140-6736(15)60907-226090645
   PubMed Web of Science ®Google Scholar
• Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int. 2008;74(9):1192–1196. doi:10.1038/ki.2008.39718716604
   PubMed Web of Science ®Google Scholar
• Massella L, Mekahli D, Paripović D, et al. Prevalence of hypertension in children with early-stage ADPKD. Clin J Am Soc Nephrol. 2018;13(6):874–883. doi:10.2215/CJN.1140101729674338
   PubMed Web of Science ®Google Scholar
• National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 114(2 Suppl 4th Report):555–576. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15286277. Accessed February 10, 2017.15286277
   PubMed Web of Science ®Google Scholar
• Cushman WC, Whelton PK, Fine LJ, et al. SPRINT trial results. Hypertension. 2015;67(2):263–265. doi:10.1161/hypertensionaha.115.0672226553234
   PubMed Web of Science ®Google Scholar
• Torres VE. Water for ADPKD? Probably, yes. J Am Soc Nephrol. 2006;17(8):2089–2091. doi:10.1681/ASN.200606060316837639
   PubMed Web of Science ®Google Scholar
• Wong ATY, Mannix C, Grantham JJ, et al. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open. 2018;8(1):e018794. doi:10.1136/bmjopen-2017-018794
   PubMed Web of Science ®Google Scholar
• Torres VE, Abebe KZ, Schrier RW, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2016;91(2):493–500. doi:10.1016/j.kint.2016.10.01827993381
   PubMed Web of Science ®Google Scholar
• Smyth A, O’Donnell MJ, Yusuf S, et al. Sodium intake and renal outcomes: a systematic review. Am J Hypertens. 2014;27(10):1277–1284. doi:10.1093/ajh/hpt29424510182
   PubMed Web of Science ®Google Scholar
• Cianciaruso B, Bellizzi V, Minutolo R, et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab. 1998;24(4):296–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9554571. Accessed January 17, 2019.9554571
   PubMedGoogle Scholar
• Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, et al. Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. a secondary analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017;13(2):109–120. doi:10.2174/157340211366617042714281528460625
   PubMed Web of Science ®Google Scholar
• Cadnapaphornchai MA, George DM, McFann K, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9(5):889–896. doi:10.2215/CJN.0835081324721893
   PubMed Web of Science ®Google Scholar
• Torres VE, Grantham JJ, Chapman AB, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6(3):640–647. doi:10.2215/CJN.0325041021088290
   PubMed Web of Science ®Google Scholar
• Grampsas SA, Chandhoke PS, Fan J, et al. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53–57. doi:10.1053/AJKD.2000.826610873872
   PubMed Web of Science ®Google Scholar
• Baishya R, Dhawan DR, Kurien A, Ganpule A, Sabnis RB, Desai MR. Management of nephrolithiasis in autosomal dominant polycystic kidney disease - A single center experience. Urol Ann. 2012;4(1):29–33. doi:10.4103/0974-7796.9161822346098
   PubMedGoogle Scholar
• Bhasin B, Alzubaidi M, Velez JCQ. Evaluation and management of gross hematuria in autosomal dominant polycystic kidney disease: a point of care guide for practicing internists. Am J Med Sci. 2018;356(2):177–180. doi:10.1016/J.AMJMS.2017.11.01330219160
   PubMed Web of Science ®Google Scholar
• Sallée M, Rafat C, Zahar J-R, et al. Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2009;4:1183–1189. doi:10.2215/CJN.0187030919470662
   PubMed Web of Science ®Google Scholar
• Telenti A, Torres VE, Gross JB, Van Scoy RE, Brown ML, Hattery RR. Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc. 1990;65(7):933–942. doi:10.1016/s0025-6196(12)65154-42198396
   PubMed Web of Science ®Google Scholar
• Pirson Y, Chauveau D, Torres V. Management of cerebral aneurysms in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2002;13(1):269–276. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11752048. Accessed May 22, 2019.11752048
   PubMed Web of Science ®Google Scholar
• Ring T, Spiegelhalter D. Risk of intracranial aneurysm bleeding in autosomal-dominant polycystic kidney disease. Kidney Int. 2007;72(11):1400–1402. doi:10.1038/sj.ki.500248817882153
   PubMed Web of Science ®Google Scholar
• Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant. 2014;29(2):247–254. doi:10.1093/ndt/gft43724215018
   PubMed Web of Science ®Google Scholar
• Jacquet A, Pallet N, Kessler M, et al. Outcomes of renal transplantation in patients with autosomal dominant polycystic kidney disease: a nationwide longitudinal study. Transpl Int. 2011;24(6):582–587. doi:10.1111/j.1432-2277.2011.01237.x21352383
   PubMed Web of Science ®Google Scholar
• Kanaan N, Devuyst O, Pirson Y. Renal transplantation in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2014;10(8):455–465. doi:10.1038/nrneph.2014.10424935705
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Watarai Y, Kobayashi T, et al. Kidney volume changes in patients with autosomal dominant polycystic kidney disease after renal transplantation. Transplantation. 2012;93(8):794–798. doi:10.1097/TP.0b013e318246f91022491657
   PubMed Web of Science ®Google Scholar
• Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet (London, England). 2007;369(9569):1287–1301. doi:10.1016/S0140-6736(07)60601-1
   PubMed Web of Science ®Google Scholar
• Caroli A, Perico N, Perna A, et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet. 2013;382(9903):1485–1495. doi:10.1016/S0140-6736(13)61407-523972263
   PubMed Web of Science ®Google Scholar
• Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363(9):830–840. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1003491.20581392
   PubMed Web of Science ®Google Scholar